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Abstract  
 
Background: There is uncertainty about the burden of severe outcomes 
associated with RSV and influenza in different subgroups of children defined by 
age, as well as age and presence of underlying health conditions. 
 
Methods: We have applied previously developed methodology to estimate the 
rates of influenza and RSV-associated hospitalizations with different diagnoses in 
different age subgroups of US children between the 2003-04 through the 2009-10 
seasons. 
 
Results: The average annual rates (per 100,000) of influenza and RSV-
associated hospitalizations for any cause excluding asthma (ICD-9 code 493) in 
the principal diagnosis with a respiratory cause (ICD-9 codes 460-519) in the 
diagnosis (either principal or secondary) were 173.1(95%CI (134.3,212.6)) 
(influenza) vs. 2336(2209,2463) (RSV) (age <1y); 77.9(51.1,105.2) vs. 
625.7(540,711.5) (age 1y); 56.3(40.9,72.2) vs. 324.2(275.1,375) (age 2y); 
44.6(32.9,56.6) vs. 172.2(134.2,211) (age 3y); 36.4(27.7,45.3) vs. 
89.7(60.6,117.8) (age 4y); 36.6(29.3,43.9) vs. 62.3(38.8,86.4) (ages 5-6y); 
20.5(16.3,24.6) vs. 30.2(16.1,43.9) (ages 7-11y); and 16.1(10.6,21.7) vs. 
36.9(17.8,55.9) (ages 12-17y). The rates of RSV-associated hospitalizations with 
asthma as a secondary (non-principal) diagnosis were 162.6(143.6,181.6) (age 
<1y), 144.7(120.8,168.2) (age 1y), 99.5(82.3,116.8) (age 2y), 60.9(46.4,75.3) 
(age 3y), 23.5(10.7,36.4) (age 4y), 16.1(5.1,27) (ages 5-6y), 11.4(4.7,18.3) (ages 
7-11y), and 15.8(4.9,26.7) (ages 12-17y).  
 
Conclusions: The estimated rates of RSV-associated hospitalizations in young 
children are high, with those rates declining rapidly with age. We hope that such 
estimates could provide one of the ingredients for evaluating the potential impact 
of RSV vaccine administration in young children. Additionally, the estimated rates 
of RSV-associated hospitalizations with asthma as a secondary diagnosis in 
young children, combined with data on the prevalence of asthma in those age 
groups suggest very high rates of RSV-associated hospitalizations in young 
children with asthma. Those children may be considered as potential target 
groups for RSV-related mitigation efforts. 
 
 
Introduction 
 
There is uncertainty about the burden of severe outcomes associated with the 
circulation of respiratory viruses such as RSV and influenza in different 
subgroups of children defined by age, as well as age and presence of underlying 
health conditions. Community studies (e.g. [1-3]) reveal various important 
aspects of the epidemiology of respiratory viruses, such as the high rates of 
RSV-associated hospitalizations in infants (particularly pre-term infants [1,2]) and 
young children, and the frequency of underlying health conditions among the 
severe outcomes (e.g. the high prevalence of asthma among hospitalized 
children infected with RSV, [1]), etc. At the same time, such studies are subject to 
limitations such as under-detection of cases of infection, and sample size 
considerations. Hospital discharge data under-represent the contribution of the 
respiratory viruses in the diagnoses; moreover, some of those diagnoses may be 
subject to misspecification of the viral etiology. Attempts at rectifying this (e.g. by 
attributing certain proportions of hospitalizations with certain diagnoses to 
respiratory viruses, [4]) are subject to uncertainty. Statistical inference (e.g. [5-8]) 
is a common approach for estimating the contribution of respiratory viruses to the 
burden of severe outcomes.  However, various assumptions underlying statistical 
models are uncertain [9,10]; moreover, when one varies the structure of 
inference models applied to the same data, the resulting goodness-of fit, and the 
estimates of the contribution of respiratory viruses vary as well ([11,12], 
Supporting Information). Overall, uncertainty about the burden of severe 
outcomes associated with respiratory viruses limits the design of mitigation 
efforts and contributes to the fact that current options for prevention and 
treatment of infections associated with viruses other than influenza are very 
limited. Major efforts are currently underway towards the development RSV 
vaccines, with over 60 candidate vaccines being in different stages of 
development in 2016 [13-15]. At same time, partly owing to the uncertainty about 
the severe outcome burden associated with RSV, target groups for those 
vaccines are uncertain. 
 
In our earlier work [11,12], we have introduced a new method for estimating the 
burden of severe outcomes associated with influenza and RSV. That method 
addresses several limitations of previously employed inference methods  
including utilization of proxies for the incidence of RSV and influenza (sub)types 
(A/H3N2, A/H1N1, and B) that are expected to be linearly related to the 
population incidence of those viruses, a relationship that is more biologically 
plausible [9,10]; utilization of the flexible model for the baseline of severe 
outcomes not associated with influenza and RSV; application of a bootstrap 
method for the confidence bounds on the estimates of the severe outcome 
burden associated with influenza and RSV that accounts for auto-correlation in 
the time series for the noise; and other constructs. In this paper we apply these 
methods [11,12] to data on US hospitalizations between the 2003-04 through the 
2009-10 seasons. We estimate the rates of influenza and RSV-associated 
hospitalizations for several diagnoses in various age-groups of children. Our 
main goals are to provide a granular evaluation (by year of age) of the RSV-
associated hospitalization burden in the young children, and to examine the 
finding in [1] about the high prevalence of asthma among hospitalized children 
infected with RSV. 
 
 
Methods 
 
Data 
We used weekly data on US hospitalizations with different diagnoses in different 
age groups of children (<1y,1y,2y,3y,4y,5-6y,7-11y,12-17y). For our analyses, we 
included 22 states for which data on hospitalizations in infants with RSV in the 
principal diagnosis exhibited consistency throughout the study period (see next 
subsection). Those 22 states  constituted approximately 63.2% of the US 
population during the study period ("AR" "CA" "CT" "GA" "HI" "IL" "IN" "MD" "MN" 
"NC" "NE" "NJ" "NV" "NY" "OH" "OR" "TN" "TX" "VA" "VT" "WA" "WI"). 
Incidence proxies for the major influenza (sub)types are derived using the US 
CDC influenza surveillance data [16]. 
 
Inference Scheme 
Our methodology is based on the framework developed in [12].  
 
Each season was defined as a period between calendar week 27 of a given year, 
and calendar week 26 of the following year. 
 
For the influenza incidence proxies, we utilize the US CDC surveillance data [16]. 
We combine the weekly state-specific data on the percent of medical 
consultations in the US CDC Outpatient Illness Surveillance Network (ILINet) that 
were for influenza-like illness with data on testing of respiratory specimens for the 
major influenza (sub)types (A/H3N2, A/H1N1, and influenza B) to define state-
specific weekly proxies for the incidence of each of the major influenza (sub)type: 
  
Weekly influenza (sub)type incidence proxy =                                                (1) 
= % Consultations for ILI * % Specimens testing positive for the (sub)type 
Our analyses pertain to the collection of 22 US states described in the Data 
subsection, and the incidence proxy for this collection of states is defined as the 
sum of state-specific incidence proxies weighted by the state populations (with 
state populations during various weeks estimated through linear interpolation (in 
time) for the yearly, July 1st estimates in [28]) . 
We consider the weekly incidence proxy for RSV to be the rate of hospitalizations 
with the principal diagnosis of RSV among children aged <1y during that week. 
We use hospitalization rates in infants because we seek a proxy proportional to 
RSV incidence in the population, and there is an apparent upward trend in annual 
rates of hospitalizations with the principal diagnosis of RSV in all age groups 
above 2 years of age, likely due to changes in testing/diagnostic practices, with 
no apparent trend in the rates of hospitalization with a principal diagnosis of RSV 
in infants. We note that in our earlier work [12], we used rates of RSV 
bronchiolitis in infants as a proxy for RSV incidence because of evidence in the 
literature (e.g. [17]) that the vast majority of bronchiolitis diagnoses were 
supported by laboratory tests. For this study, we were not in possession of data 
on RSV bronchiolitis in infants. At the same time, practices for testing for viral 
infections following a bronchiolitis diagnosis have changed over time, and 
laboratory testing is no longer recommended in the US [18]. We also note that 
rates of hospitalizations in infants with RSV in the principal diagnosis may not be 
proportional to RSV incidence rates because presence of RSV in the principal 
diagnosis need not be supported by a laboratory test. Correspondingly, 
diagnostic practices may vary by place (e.g. hospitalizations in infants with 
symptoms that are often associated with RSV infections, such as wheezing, may 
result in RSV diagnoses without confirmation by laboratory testing more often in 
some places compared to others). Additionally, temporal trends in diagnostic 
practices (e.g. ones resulting from changes in testing practices) may also be 
present in certain locations. We’ve tried to adjust for such potential biases by 
excluding states with an apparent trend in the rates of hospitalizations in infants 
with RSV in the principal diagnosis, as well as states for which annual rates of 
hospitalizations in infants with RSV in the principal diagnosis are noticeably 
higher than in most states.  
 
We note, as we did in [12], that the relation between an influenza incidence proxy 
and the rate of associated hospitalizations in a given age group may change in 
time due to a variety of factors. In particular, changes in the age distribution for 
different influenza-associated outcomes, e.g. the rise in the proportion of school-
age children during seasons when novel influenza strains were circulating are 
known to have taken place. For example, the 2003-04 influenza season was 
driven by a novel (Fujian) A/H3N2 strain. Results in [8] suggests that the rates of 
excess ED visits for school-age children compared to pre-school children were 
higher during the 2003-04 season compared to the 2004-05 season. Similarly, 
the emergence of the pandemic A/H1N1 influenza strain in 2009 resulted in 
exceptionally high rates of pediatric influenza infections [19], and the ratios 
between the rates of A/H1N1-associated hospitalizations in different subgroups 
of children and the A/H1N1 incidence proxy are potentially different for the 
pandemic strain compared to the seasonal A/H1N1 strain. Based on those 
considerations, we split the A/H3N2 incidence proxy into two, namely H31 
equaling the A/H3N2 proxy for the 2003-04 season, and being zero afterwards, 
and H32, being zero for the 2003-04 season, and equaling the A/H3N2 incidence 
proxy afterwards. Similarly, we split the A/H1N1 incidence proxy into two, 
reflecting A/H1N1 incidence before and after the 2009 pandemic.  
 
The outcomes we consider are hospitalizations with different diagnoses in 
different age groups of children. The four types of hospitalization diagnoses used 
in our analyses are: diseases of the respiratory system excluding asthma (ICD 9 
codes 460-519 excluding 493); pneumonia and influenza (ICD9 codes 480-488); 
any code excluding asthma in the principal diagnosis with a respiratory code in 
the principal or secondary diagnoses; and asthma as a secondary (non-principal) 
diagnosis (see the next sub-section). For each outcome of interest, weekly rates 
for this outcome during the study period are regressed linearly against the 
incidence proxies for influenza, RSV, as well as temporal trend (modeled by a 
low degree polynomial in time) and a seasonal baseline (modeled by cubic 
splines in the calendar week with knots at every fourth week and with annual 
periodicity) [11,12]. If  is the weekly rate for the outcome of interest on week 
, and  are the incidence proxies for the various influenza (sub)types (split 
into time periods as described above) and RSV, the model structure is 
 
                                    (2) 
 
To account for the autocorrelation structure in the noise, a bootstrap method 
devised in [11] is used to prescribe the confidence bounds for the model’s 
estimates. Estimates in [12] suggest that several alternative inference methods 
(such as maximal likelihood estimation under the AR(1) assumption on the noise) 
yield very similar results. 
 
Asthma-related hospitalizations 
While we’ve estimated the rates of influenza and RSV-associated hospitalizations 
with asthma as a secondary (non-principal) diagnosis, hospitalizations for asthma 
(as the principal diagnosis) were excluded from the analysis. Briefly, this was 
done because asthma hospitalizations do not accord well with the structure of the 
inference model (eq. 2), as suggested both by visual inspection and 
inconsistencies in the estimates provided by the models.  
 
If one assumes that for RSV-associated hospitalizations in children with asthma 
in the secondary diagnosis, asthma was present in those children before the RSV 
infection (see the penultimate paragraph of the Discussion) then the rates of 
RSV-associated hospitalizations with asthma in the secondary diagnosis in 
children with asthma in a given age group equal the corresponding rates in all 
children in that age group divided by the prevalence of asthma in that age group.  
 
 
	O(t)
	t 	Vi(t)
	O(t)= βi ⋅Vi(t)+Baseline+Trend +Noisei∑
Results 
 
Tables 1 and 2 present the estimates of the average annual rates of 
hospitalizations associated with influenza and RSV for various diagnoses in 
select age subgroups of children. Table 1 exhibits the results for hospitalizations 
for respiratory causes (excluding asthma) in the principal diagnosis, as well as for 
any cause excluding asthma in the principal diagnosis with a respiratory cause in 
either the principal or secondary diagnosis. Table 2 presents the corresponding 
results for hospitalizations for Pneumonia and Influenza (P&I) in the principal 
diagnosis, as well for hospitalizations with asthma as a secondary (non-principal) 
diagnosis. 
 
Given the low prevalence of asthma in young children (4.7% among children 
under the age of 5y, [20]), our estimates suggest that the rates of RSV-
associated hospitalizations in young children with asthma are very high. In fact 
this already follows from the estimates of the rates of RSV-associated 
hospitalizations with asthma as a secondary diagnosis in young children 
(Methods), with further contribution represented by RSV-associated 
hospitalizations with asthma as the principal diagnosis, as well as RSV-
associated hospitalizations in children with asthma for which asthma does not 
appear in the diagnosis – see Discussion.  
 
For any studied age group and diagnosis (save for P&I hospitalizations in 
children aged 7-11y), the estimated rates of RSV-associated hospitalizations are 
higher than the estimated rates of influenza-associated hospitalizations. The 
estimated rates of RSV-associated hospitalizations for any principal diagnosis 
(excluding asthma) with a respiratory cause in the diagnosis (either principal or 
secondary, Table 1) are high in young children, though they decline rapidly with 
age. For the more restricted category of respiratory causes in the principal 
diagnosis, the rates of RSV-associated hospitalizations were somewhat lower 
(Table 1); the corresponding rates of RSV-associated hospitalizations with P&I in 
the principal diagnosis were further lower, particularly for infants aged <1y (Table 
2).  
 
Age group / 
Diagnosis 
Respiratory cause (excluding 
asthma) in the principal 
diagnosis 
Hospitalizations (excluding 
asthma) with respiratory cause in 
principal or secondary diagnosis 
Flu RSV Flu RSV 
<1y 134.6 
(107,162.9) 
2106 
(2017,2193) 
173.1 
(134.3,212.6) 
2336 
(2209,2463) 
1y 62.7 
(38.6,87.6) 
549.2 
(475.2,625.2) 
77.9 
(51.1,105.2) 
625.7 
(540,711.5) 
2y 41.8 
(29,54.9) 
264.6 
(222.9,305.4) 
56.3 
(40.9,72.2) 
324.2 
(275.1,375) 
3y 32.3 
(23.1,41.7) 
142.7 
(113.9,172.5) 
44.6 
(32.9,56.6) 
172.2 
(134.2,211) 
4y 25.6 
(18.8,32.4) 
63.9 
(42,85.4) 
36.4 
(27.7,45.3) 
89.7 
(60.6,117.8) 
5-6y 27.2 
(21.6,32.7) 
42.2 
(24.2,59.6) 
36.6 
(29.3,43.9) 
62.3 
(38.8,86.4) 
7-11y 14.6 
(12.2,17) 
18 
(10.4,25.4) 
20.5 
(16.3,24.6) 
30.2 
(16.1,43.9) 
12-17y 9.8 
(8.4,11.3) 
14.6 
(9.7,19.4) 
16.1 
(10.6,21.7) 
36.9 
(17.8,55.9) 
 
Table 1: Average annual rates of hospitalization per 100,000 associated with 
influenza and RSV for respiratory causes excluding asthma in the principal 
diagnosis (ICD-9 codes 460-519 excluding 493), and for any principal diagnosis 
excluding asthma with a respiratory cause in the principal or secondary 
diagnoses in select groups of US children, 2003-04 through 2009-10 seasons. 
 
Age group / 
Diagnosis 
Pneumonia and Influenza in 
the principal diagnosis 
Asthma as a secondary  
(non-principal) diagnosis 
Flu RSV Flu RSV 
<1y 105.9 
(84.4,127.9) 
340.7 
(276.5,403.5) 
5.1 
(-0.7,11) 
162.6 
(143.6,181.6) 
1y 55.6 
(43.2,68.4) 
241.2 
(200.8,281.8) 
10 
(2.8,17.3) 
144.7 
(120.8,168.2) 
2y 35.1 
(27.1,43) 
151.7 
(125.8,178.1) 
9.2 
(3.9,14.5) 
99.5 
(82.3,116.8) 
3y 28.1 
(20.4,36.1) 
94.8 
(70.6,119.4) 
8 
(3.8,12.3) 
60.9 
(46.4,75.3) 
4y 21.8 
(16.6,27.2) 
44.9 
(27.9,61.7) 
6.3 
(2.6,10.2) 
23.5 
(10.7,36.4) 
5-6y 21.2 
(16.5,26) 
29.6 
(14,44.5) 
7.2 
(3.9,10.5) 
16.1 
(5.1,27) 
7-11y 11.2 
(9.3,13.1) 
10.9 
(4.9,16.9) 
5 
(3.1,7) 
11.4 
(4.7,18.3) 
12-17y 7.9 
(7,8.8) 
8 
(5,11) 
2.2 
(-1,5.4) 
15.8 
(4.9,26.7) 
 
Table 2: Average annual rates of hospitalization per 100,000 associated with 
influenza and RSV for P&I (ICD9 codes 480-488), and asthma as a secondary 
(non-principal) diagnosis in select groups of US children, 2003-04 through 2009-
10 seasons. 
 
 
Discussion 
 
While major efforts are currently under way towards the development of RSV 
vaccines [13-15], the design of the corresponding vaccination strategies (and 
other mitigation efforts) is limited by the uncertainty about the severe outcome 
burden associated with RSV. In this paper we apply the previously developed 
methodology [11,12] to estimate the rates of influenza and RSV-associated 
hospitalizations with various diagnoses in different age subgroups of US children 
between 2003-2010. Our estimates suggest that the rates of RSV-associated 
hospitalizations in young children are high, though they decline rapidly by year of 
age. Additionally, our results suggest that the rates of RSV-associated 
hospitalizations in young children with asthma are extremely high, making those 
children potential targets for related mitigation efforts. Indeed, the US CDC 
estimates suggest prevalence of 4.7% for asthma in children under the age of 5y 
in 2015 [20]. Combining this with the estimates in Table 2 (Methods) tells that the 
rates of RSV-associated hospitalizations with asthma in the secondary diagnosis 
per 100,000 children with asthma are 3460(3055,3864) (age <1y); 
3079(2570,3579) (age 1y); 2117(1751,2485) age (2y); 1296(987,1602) (age 3y), 
etc.; those estimates are in addition to RSV-associated hospitalizations with 
asthma in the principal diagnosis, or not appearing in the diagnosis. We note that 
estimates of the prevalence of asthma in young children may be subject to under-
detection. Even if the true prevalence of asthma in young children is higher than 
the estimates in [20], closer to the 10% rate for older children [20], this still 
suggests that for children under the age of 2y with asthma, the annual rates of 
RSV-associated hospitalizations with asthma in the secondary diagnosis alone 
are around 1,500/100,000, with the corresponding rate being around 
1,000/100,000 for children aged 2y, etc. 
 
While the connection between RSV infection in early childhood and the 
subsequent risk of developing asthma has received a lot of attention in the 
literature [21,25-27], the contribution of RSV to the hospitalizations burden for 
children with asthma is less studied [22]. The results in [1] suggest high 
frequency of RSV infections in hospitalized children under the age of 5y, with a 
high proportion of RSV-infected hospitalized children having asthma. Other 
studies have found high frequency of RSV infections in hospitalized young 
children with underlying health conditions, including asthma [23,24]. Our 
estimates of the rates of RSV-associated hospitalizations with asthma as a 
secondary diagnosis support the results of those studies, providing further 
evidence about the very high rates of RSV-associated hospitalizations in young 
children with asthma.  
 
Our paper has some limitations. One of them is the accuracy of the proposed 
regression framework [11,12]. Spikes in hospitalization rates during certain 
influenza seasons correspond visually to major influenza epidemics (as 
suggested by the incidence proxies that we utilize), providing additional support 
for the validity of our inference method for influenza-associated hospitalization 
rates. Inclusion of RSV into the model can be more problematic due to the high 
periodicity of its circulation and the difficulty of separating its contribution from the 
annual baseline of hospitalization rates not associated with influenza and RSV. 
Additionally, we’ve used rates of hospitalizations in infants with RSV in the 
principal diagnosis as proxy for RSV incidence, while presence of RSV in the 
principal diagnosis need not be supported by a laboratory test. We’ve tried to 
remedy this by excluding states where rates of hospitalization in infants with RSV 
in the principal diagnosis were noticeably higher than average (which might 
suggest admixture from other etiologies in that category of hospitalizations) from 
the analyses (see Methods). While the resulting confidence bounds for the 
contribution of RSV to many of the hospitalization categories that we’ve 
considered are reasonably tight (Tables 1 and 2), further work is needed to 
evaluate the accuracy of our inference methodology. It is not entirely clear 
whether for RSV-associated hospitalizations in children with asthma in the 
secondary diagnosis, asthma was present before the RSV infection, or 
developed between the RSV infection and hospitalization. We assume that for 
the overwhelming majority of those children, the former is the case. While the 
connection between severe RSV infection and the subsequent development of 
asthma was studied by various authors [25-27], this development doesn’t appear 
to take place immediately. It has been suggested ([26]) that a severe RSV 
episode initiates a series of immunologic events that eventually result in asthma. 
Finally, while we estimated the rates of influenza and RSV-associated 
hospitalizations with asthma as a secondary (non-principal) diagnosis, we could 
not estimate the corresponding rates for hospitalizations with asthma as a 
principal diagnosis (see Methods). Nonetheless, our results for hospitalizations 
with asthma as a secondary diagnosis already suggest very high rates of RSV-
associated hospitalizations for young children with asthma. 
 
We believe that despite those limitations, our work provides a granular 
assessment of the hospitalization burden associated with influenza and RSV in 
young children that may represent one of the ingredients for evaluating the 
impact of RSV vaccination in young children. Additionally, our results suggest 
very high rates of RSV-associated hospitalization in young children with asthma. 
Those children may be considered as potential target groups for RSV-related 
mitigation efforts, such as palivizumab prophylaxis. 
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